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The mast cells participate in inflammation and possibly in carcinogenesis. The aim
of the study was to study mast cells in melanocytic lesions. The material consisted
of 24 pigmented nevi, 18 dysplastic nevi and 19 melanomas. The sections were stained
immunohistochemically for tryptase and chymase. Positive cells were counted inside
the lesions and at the interface between the lesion and dermis.
The mean intralesional tryptase+ count was 15.75 for nevi, 21.78 for dysplastic nevi,
and 8.07 for melanomas. The chymase+ intralesional count was 14.89 for nevi, 21.88
for dysplastic nevi, and 11.34 for melanomas. The tryptase+ perilesional count was
16.89 for nevi, 15.93 for dysplastic nevi, and 15.71 for melanomas. The chymase+
perilesional count was 16.52 for nevi, 16.16 for dysplastic nevi, and 14.77 for
melanomas. The tryptase/chymase intralesional ratio was 0.93 for nevi, 1.05 for dys-
plastic nevi, and 1.67 for melanomas. The tryptase/chymase perilesional ratio was
1.02 for nevi, 1.09 for dysplastic nevi, and 1.00 for melanomas. The differences be-
tween intralesional mast cells, both tryptase+ and chymase+, were statistically sig-
nificant. The intralesional tryptase+ count showed an inverse correlation to age
(R = –0.42); this correlation was the strongest in melanomas.
The results obtained in our study suggest a possible correlation between mast cells
and the pathogenesis of cutaneous melanoma.
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Introduction
Melanocytic nevi of the skin are fairly common. The
details of the transition from a common nevus to a dys-
plastic nevus and ultimately to a melanoma are in-
tensively studied, but remain incompletely understood.
In cancer pathology and therapy there is an increasing
interest in the interactions between the cancer cells
themselves and their environment, including the con-
nective tissue stroma, the newly forming vessels and in-
flammatory elements. In particular, the relationship be-
tween inflammatory process and cancer is complex and
only partially understood. It has been theorized that
inflammation may be the source of growth factors for
the cancer, and that cancer growth itself is controlled
by immunologic and inflammatory mechanisms.
Chronic inflammatory mechanisms are also responsi-
ble for neoangiogenesis required for the continuous
growth of cancer. One of the cells known to actively
participate in the chronic inflammatory process, yet not
extensively studied, is the mast cell. The paucity of in-
formation may be due to the difficulty of visualizing
mast cells in the tissue sections by routine stain or due
to the ability of the mast cells to imitate other connective
tissue or inflammatory cells. Generally, at least two dif-
ferent populations of mast cells were described; one ex-
pressing both chymase and tryptase, and the other with
sole tryptase expression. In different body sites, mast
cell populations are differently represented, and they
may differ in their functions [1-5].
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The aim of the study was to compare the repre-
sentation of chymase- and tryptase-positive mast
cells in melanocytic lesions of the skin and in their im-
mediate proximity.
Material and methods
All the cases were obtained from the files of the De-
partment of Pathomorphology. The material was fixed
in buffered formalin, processed by the routine
method and embedded in paraffin. Four µm sections
were cut from the paraffin blocks. Primary anti-
tryptase antibody (clone AA1, Novocastra, UK) at
1 : 100 dilution and anti-chymase antibody (clone
CC1, Abcam, UK) at 1 : 100 dilution were used. Anti-
gen retrieval was carried out by microwaving in cit-
rate buffer (pH 6.0) for 5 min at 700 W, then for
5 minutes at 600 W for chymase stain and by trypsin
digestion (30 min at 37°C) for tryptase stain. The EN-
VISION + System kit (DAKO, Denmark) detection
system was used. 3-amino-9-ethylcarbazole (DAKO,
Denmark) was used as chromogen. The immuno-
stained slides were examined under Optech microscope
(Optech Microscope Services Limited, UK) equipped
with a 40× lens (field of vision diameter: 0.45 mm).
For each stain, two separate counts were performed.
For the intralesional count, the entire area of the
melanocytic lesion was scanned, and the im-
munopositive cells as well as the number of fields were
recorded. For the perilesional count, only the fields
of view along the interface between the lesion and its
neighbourhood were chosen, and then the number of
positive cells and fields were recorded. The results were
expressed as the average number of positive cells per
high power field. The statistical analysis was performed
using Statistica 9.0 (StatSoft Inc, USA). The Kruskal-
Wallis ANOVA with multiple post-hoc comparison
tests, the Mann-Whitney U test, and the Spearman
correlation coefficient were used. The significance lev-
el was set as p = 0.05.
Results
The material included 61 skin biopsies from 54 pa-
tients, and consisted of 24 common pigmented nevi,
18 dysplastic nevi and 19 melanomas. The female/male
ratio was 25 to 29, and the mean age was 41.1 (range
11 to 86, SD 20.25).
In the common pigmented nevus group, the fe-
male/male ratio was 11 to 10, and the mean age was
26.62 (range 11 to 65, SD 13.89); in the dysplastic ne-
vus group the female/male ratio was 6 to 8, and the
mean age was 36.29 (range 20 to 63, SD 13.84); in
the melanoma group the female/male ratio was 19 to
11, and the mean age was 60.68 (range 41 to 86, SD
13.66).
Most of the melanomas were of the nodular
melanoma type (15, i.e. 78.9%), two cases were su-
perficial spreading melanomas and single cases included
spitzoid melanoma and a melanoma originating from
the melanocytic nevus. The average infiltrate thickness
according to Breslow was 2.78 mm (range 0.60 to
7 mm, SD 1.97). The average number of mitotic fig-
ures was 15.68 per mm2 (range 1.00 to 50, SD 15.47).
The counts of mast cells are shown in Table I and
Fig. 2. According to Kruskal-Wallis ANOVA test, there
were significant differences between groups in the in-
tralesional mast cell counts. For tryptase-positive
cells (Kruskal-Wallis H = 20.86, p < 0.01), the post-
hoc multiple comparison test showed variations that
were due to the difference between the melanomas and
both the common pigmented and dysplastic nevi. For
chymase-positive cells (Kruskal-Wallis H = 8.90,
p < 0.012), the post-hoc multiple comparison test
showed variation due entirely to the difference between
melanomas and dysplastic nevi. Slight differences
were also seen in the intralesional chymase / tryptase
ratio, but these did not reach statistical significance
(Kruskal-Wallis H = 4.83, p > 0.09). Differences in
perilesional mast cell counts were not statistically sig-
nificant (tryptase-positive cells Kruskal-Wallis
H = 0.84, p > 0.65, chymase-positive cells Kruskal-
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Fig. 1. Mast cells in melanocytic nevi and melanomas. A – common pigmented nevus, B – dysplastic nevus,
C – melanoma. Immunohistochemistry for tryptase, original magnification 400×
A B C
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Wallis H = 1.75, p > 0.40), and the chymase / tryptase
ratio (H = 0.86, p > 0.64). The intralesional tryptase-
positive cell counts showed a significant, inverse cor-
relation to patients’ age (R = –0.42, p < 0.002); this
correlation was the strongest in the melanoma group
(R = –0.47, p < 0.05), but was weaker and not sig-
nificant in both common and dysplastic nevi. It is worth
noting that the age-mast cell count correlation was pos-
itive in common nevi (R = 0.17), but negative in dys-
plastic nevi (R = –0.30), like in melanomas. There were
no differences in mast cell counts related to the sex of
the patients.
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Table I. Values of the mast cell counts
TRYPTASE CHYMASE TRYPTASE CHYMASE TRYPTASE/ TRYPTASE/
INTRALESIONAL INTRALESIONAL PERILESIONAL PERILESIONAL CHYMASE CHYMASE
INTRALESIONAL PERILESIONAL
MEAN (SD) MEAN (SD) MEAN (SD) MEAN (SD) MEAN (SD) MEAN (SD)
Pigmented 15.75 (9.01) 14.89 (9.37) 16.89 (7.59) 16.52 (7.33) 0.93 (0.26) 1.02 (0.21)
nevi
Dysplastic 21.78 (10.80) 21.88 (14.44) 15.93 (8.30) 16.16 (5.59) 1.05 (0.43) 1.09 (0.31)
nevi
Melanomas 8.07 (5.53) 11.34 (8.25) 15.71 (7.35) 14.77 (6.64) 1.67 (1.51) 1.00 (0.31)
All cases 14.90 (10.04) 15.66 (11.29) 16.24 (7.62) 15.87 (6.58) 1.21 (0.95) 1.03 (0.27)
SD – standard deviation of mean
40
35
30
25
20
15
10
5
0
tryptase
40
35
30
25
20
15
10
5
0
chymase
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
tryptase/chymase ratio
in
tr
al
es
io
na
l
26
24
22
20
18
16
14
12
10
8
6
tryptase
26
24
22
20
18
16
14
12
10
8
6
chymase
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
tryptase/chymase ratio
pe
ri
le
si
on
al
nevus dysplastic melanoma
nevus
nevus dysplastic melanoma
nevus
nevus dysplastic melanoma
nevus
Fig. 2. The number of immunopositive cells in the melanocytic lesions under study. Tryptase-positive cells on the left,
chymase-positive in the centre, and tryptase-chymase count ratio on the right. Upper row – intralesional mast cells;
lower row – perilesional mast cells. Central point is the arithmetic mean, box is the arithmetic mean ± standard error
of mean, whisker is the arithmetic mean ± standard deviation of mean
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Discussion
Mast cells are difficult to visualize on routine
stains, and they may be easily mistaken for other in-
flammatory cells. As a consequence, a variety of spe-
cial stains is used; the classical one is the toluidine blue
stain; however, histochemical stains may be technically
tricky and difficult to interpret. Immunohistochemistry
for CD117 or tryptase is thought to mark all the mast
cells both specifically and sensitively, and may be used
for assessing their total number. However, chymase,
another mast-cell specific proteinase, is detected in a sub-
set of mast cells only. Therefore, two separate popu-
lations of mast cells may be recognized, tryptase pos-
itive and tryptase-chymase positive. The function of chy-
mase is particularly important in circulatory and renal
disease. It is also important in arterial hypertension as
it is able to function as an alternative convertase in the
renin-angiotensin axis [1, 3, 4]. The mast cells are well
known to participate in the inflammatory process,
especially if an allergic component is present. The proin-
flammatory function of the mast cell may depend on
different mediators, including tryptase itself, as well as
chymase, histamine and several cytokines [6]. The re-
lationship between inflammation, mast cells and can-
cer might be quite complicated, featuring both pro-
motion and inhibition of the tumour growth. Pro-neo-
plastic stimuli include the following: the promotion of
neoangiogenesis, the promotion of tumour growth by
the factors released by the mast cell, the production of
the proteases facilitating migration of tumour cells and
immunosuppression. The anti-neoplastic actions might
include direct inhibition of cell growth, increased in-
flammatory anti-tumour reaction, induction of apop-
tosis and decreased cell mobility. The opposite effects
of the same mast cell might depend on its ability to de-
granulate or secrete specific mediators in response to
a variance of stimuli. Mast cells might also be able to
recruit both M1 and M2 macrophages, which are well
known to have opposite effects on tumour growth. An-
other important factor is the heterogeneity of the mast
cells, especially the presence of both chymase-positive
and chymase-negative cells; these may differ in their
products and also in response to stimuli [7]. The par-
ticipation of the mast cells in both the progression of
cancer and in neoangiogenesis has been shown in sev-
eral cancer types; specifically pulmonary carcinoma [8],
colorectal carcinoma [9, 10], neurofibromas [11] and
various skin tumours including melanocytic nevi and
melanomas [11-16]. Proangiogenic action of mast cells
might be mediated by secretion of VEGF, angiopoi-
etin, bFGF, TGF-β, TNF-α and IL-8 [17-19]. Tryptase
also has proangiogenic action with its ability to degrade
connective tissue matrix and ability to activate PAR-
2 receptors expressed on endothelial cells [10, 20]. Chy-
mase was also shown to be pro-angiogenic [21]. The
mast cells were implicated in increased vascular per-
meability and connective matrix remodelling; these
functions may influence cancer progression and
metastatic spread. Of particular interest is that mas-
tocytes may directly influence growth of the cancer cells
[6, 9, 13, 14, 20]. Yoshii et al. showed that tryptase
may be responsible for stimulation of cancer growth,
specifically through the protease activated receptor
(PAR-2), MAP kinase activation and prostaglandin E2
release [10]. Since the PAR-2 receptor is expressed by
nevi and melanomas [22], an analogous mechanism
could be operating in melanocytic lesions; however, the
subject requires further studies. With the pleiotropic
effects the clinical significance of tumour-related mast
cells remains only partially understood. The issue is fur-
ther complicated by the existence of both intratumoral
and peritumoral mast cells with possibly divergent sig-
nificance. Most studies suggest that peritumoral mast
cells are more numerous than intratumoral; it was also
observed that intratumoral mastocytes contain less gran-
ules; this might indicate a more extensive secretion [8-
10]. Carlini et al. showed that patients with the non
small cell pulmonary carcinoma and a high chymase-
positive mast cell count inside the tumours had high-
er vascular density. It was also shown that the patients
with a higher peritumoral mast cell count had a high-
er chance of survival [8]. Mauro et al. performed a sim-
ilar analysis of colorectal carcinoma. They reported a cor-
relation between the mast cell count and vascular den-
sity, and a higher survival rate for patients with a low-
er mast cell count at the tumoral/stromal interface [9].
Ribatti et al. [23] found the density of mast cells to par-
allel microvessel density in progression of gastric car-
cinoma. This relationship was seen for both chymase
and tryptase. In addition to the clinical significance of
mast cells, their participation in the process of car-
cinogenesis is of particular interest; however, this top-
ic is not well explored. Mast cells may promote the
growth of cancer cells directly (vide supra). Mast cells
have also been shown to regulate proliferation of blood
vessels and to participate in induction of angiogenic
switch, necessary for a fully malignant phenotype. Wilk
et al. [24] have seen a stepwise increase of tryptase-pos-
itive and chymase-positive mast cells from normal mu-
cosa, to cervical intraepithelial neoplasia, and ultimately
to invasive cervical carcinoma. A similar progression
of mast cell numbers was described for oral dysplasia
and cancer [25]. In addition, the mast cells were also
shown to participate in the progression of cutaneous
tumours.
In normal skin, there are always a certain number
of mast cells present; these are predominantly of the
tryptase/chymase type. Mast cells can contribute to the
tumorigenesis of cutaneous malignancies through
different mechanisms. These mechanisms include
participation in immunosuppression, the release of
proangiogenic and mitogenic factors and involvement
in the degradation of the extracellular matrix [12]. Both
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tryptase and chymase can be involved in the growth
of some skin tumours, however, in the skin, chymase
is partially inactivated, due to effective inhibitors such
as α1-antichymotrypsin or α1-protease inhibitor [13].
Mast cells accumulate at the periphery of or within cu-
taneous neoplasms. Mast cells are recruited and acti-
vated by microenvironmental factors, tumour cells or
UVB radiation. It is hypothesized that a higher, ge-
netically predetermined density of dermal mast cell pre-
disposes to UVB induced immunosuppression. Patients
with basal cell carcinomas and melanomas share an in-
creased dermal mast cell prevalence in non-sun exposed
buttock skin [15, 16]. Increased mast cell counts were
reported in more aggressive variants of both basal cell
carcinoma and squamous cell carcinoma. This effect
seemed to be independent of the presence of an in-
flammatory infiltrate [12].
Evidence supports the mainly tumorigenic action of
mast cells in the development of cutaneous cancers;
however, their anticancer effects have also been doc-
umented. Some mediators released by mast cells
show an inhibitory effect on tumour growth and an-
giogenesis, specifically TNF-α, IL-1 and IL-6 have been
reported to suppress melanoma growth. Additional-
ly, phenotype and secretory patterns of mast cells can
be altered by microenvironmental factors, which results
in the release of specific mediators. For example, low
pH promotes IL-4 and IL-6 production without con-
comitant histamine release. Some mediators that have
well-established proangiogenic functions may para-
doxically inhibit progression of the tumour. It is pos-
tulated that histamine can increase prostacyclin syn-
thesis by endothelial cells and prostacyclin is a potent
antimetastatic factor [12]. Some studies have shown
the direct tumour cytotoxicity of mast cells. Activation
of TLR2 on mast cells and subsequent release of IL-6
results in the inhibition of tumour growth both in vit-
ro and in vivo. Recruitment of NK cells and CD3+
T cells by mast cells has also been observed [26].
The presence of mast cells within melanocytic lesions
is a well-documented phenomenon. Although the hy-
pothesis that mast cells would represent a transition-
al phase in the differentiation of melanocytes has not
been widely accepted, both types of cells share some
developmental features. C-kit (CD117) and its ligand
SCF seem to be crucial for the maturation, survival and
migration of both melanocytes and mast cells [14]. At
least two cases of combined mastocytoma-pigmented
nevus have been reported. The mast cells are observed
in typical melanocytic nevi, dysplastic nevi, in situ
melanomas and in invasive melanomas. Nevertheless,
the clinical significance of the mast cells and their role
in the development and progression of melanocytic tu-
mours remains controversial [27].
Statistically significant differences in the number of
perilesional mast cells were found between nevi and
melanomas. In several studies the increase in mast cell
counts reflected the postulated steps in the progression
of melanocytic tumours. This progression involves the
transformation of a common nevus to a dysplastic ne-
vus, then further progression into an in situ melanoma
and finally into an invasive melanoma. The lowest mast
cell count was found in the common nevi, an inter-
mediate value was seen in the dysplastic nevi and high-
est numbers of mast cells were seen in melanomas
[14, 28, 29]. It was postulated that the mast cells ac-
cumulate around melanomas and promote their
growth, specifically by the release of proangiogenic fac-
tors. In fact, peritumoral mast cell counts correlate
strongly with microvessel density, presence of the metas-
tases and prognosis [14, 17, 28, 30]. Melanoma cells
may attract mast cells by producing mast cell chemo-
tactic/mitogenic factors such as IL-3 or FGF-2. The re-
cruitment of mast cells, and subsequent release of he-
parin, bFGF, histamine, or TNF-α favours tumour pro-
gression, featuring a self-perpetuating regulatory loop
[28, 31].
In our study the perilesional mast cell density was
the lowest in the melanoma group, but the differences
between groups were not significant. This discrepan-
cy between our results and other studies can be part-
ly explained by the different methodologies applied or
different number of cases examined. Some authors vi-
sualize mast cells by toluidine blue stain, some count-
ed them over a limited area [17, 28-30], while other
studies counted the volume of the tissue occupied by
mast cells, and not the specific number of these cells
[14]. Our study counted the chymase- and tryptase-
positive cells in all available fields of view and then cal-
culated the numbers per unit area, which, in our opin-
ion, gives more reliable data. Conversely, our findings
may constitute a real phenomenon. The melanomas in
our series were relatively large tumours, with the av-
erage infiltrate thickness of 2.78 mm. It is conceivable
that at some point of tumour development its cells be-
come self-sufficient regarding angiogenesis, without the
necessity for further contribution of mast cells. Further
studies are required to clarify this issue.
Our results also reflected significant differences be-
tween groups in the intralesional mast cell counts. To
our knowledge, there are no reports analyzing the role
of intratumoral mast cells in melanocytic tumours. The
lowest mast cell count was observed in the melanoma
group, both for chymase- and tryptase-positive cells.
We believe that there are two possible explanations for
these results. Assuming that mast cells favour tumour
growth, the increasing density of intratumoral mast cells
along the postulated nevus-dysplastic nevus axis
would suggest their role at the early stages of
melanocytic carcinogenesis. This increasing density of
mast cells is then followed by a subsequent decrease
after emergence of a fully malignant phenotype.
Since angiogenesis in most pronounced at the interface
between the tumour and the stroma, intratumoral mast
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cells are likely to act by another, non-angiogenic mech-
anism. An alternative explanation might be that the in-
creasing mast cell counts from common nevi to dysplastic
nevi could be a sign of the host response against tumour
transformation into malignancy. Lower mast cell counts
in cancer might reflect the overcoming of host defences,
therefore allowing cancer growth. Alternatively, lesions
with low immune reaction (featuring low mast cell
counts) will be able to evolve into a fully malignant phe-
notype, whereas the ones promoting strong reaction (with
a high mast cells count) may remain stable.
Our results also showed an inverse correlation be-
tween intratumoral mast cells and age; this relation-
ship was particularly strong in the melanoma group.
This finding along with the fact that the advanced age
is associated with defects in all cells of the innate im-
mune system, including the decrease in number of mast
cells in the skin, may further support the idea of mast
cells as an element of immune surveillance [32].
We believe that further studies are needed to elu-
cidate the role of mast cells in melanocytic lesions.
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